ReviewCureus2026
Therapeutic Efficacy of Sirolimus in Skeletal Manifestations of Gorham-Stout Disease in Adults: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gorham-Stout disease (GSD) is a rare condition characterized by progressive osteolysis and abnormal proliferation of lymphatic vessels. Its pathogenesis involves PI3K/AKT/mTOR pathway hyperactivation, providing a molecular basis for the application of targeted mTOR inhibitors such as sirolimus. This study aims to systematically review the efficacy and safety of sirolimus in treating adult patients with GSD presenting with skeletal manifestations. A systematic review was conducted in accordance with PRISMA 2020 guidelines using PubMed, Scopus, and EMBASE databases. Data from eligible case reports involving adult patients were extracted and analyzed through a qualitative narrative synthesis. Nine case reports involving 9 patients (mean age 39.3 years) met the inclusion criteria. Patients presented with extensive polyostotic involvement and severe complications such as massive pleural effusions or recurrent chylothorax. Sirolimus therapy yielded a therapeutic response in seven out of nine patients, including two complete and five partial responses. Data from these nine case reports suggest that the intervention may effectively halt active osteolysis and promote the resolution of effusions. While the therapy successfully arrested disease progression and induced significant localized bone formation, complete anatomical reossification of all osteolytic lesions was not achieved in the adult cohort. The treatment was generally well-tolerated, with manageable adverse events (acne, mild mouth sores, hyperlipidemia, nausea, and respiratory infection). Targeted sirolimus therapy serves as a potential therapeutic option for adult GSD. It necessitates a long-term, multimodal approach, including concurrent anti-resorptive and continuous imaging follow-up. Current evidence is limited by the reliance on heterogeneous case reports. Multicenter prospective registries or international collaborative cohorts are required to validate our results and establish standardized dosing guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.